Elite Trades From Anywhere

$100 Off Your First Year

Claim Now
Last Close
22.79
Jun 30 • 01:48PM ET Dollar change-0.35 Percentage change(-1.51%)
Index
RUT
Market Cap
1.68B
Enterprise Value
1.40B
Income
504.34M
Sales
434.49M
Book/sh
18.18
Cash/sh
8.29
Employees
159
IPO
Oct 05, 2004
P/E
3.79
Forward P/E
10.17
PEG
-
P/S
3.87
P/B
1.25
P/C
2.75
P/FCF
9.24
EV/EBITDA
6.98
EV/Sales
3.23
Quick Ratio
20.07
Current Ratio
21.13
Debt/Eq
0.25
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
6.01
EPS next Y
2.24
EPS next Q
0.44
EPS this Y
8.12%
EPS next Y
-37.22%
EPS next 5Y
-14.67%
EPS past 3/5Y
- 10.35%
Sales past 3/5Y
325.77% 3.93%
EPS Y/Y TTM
836.84%
Sales Y/Y TTM
13.25%
EPS Q/Q
398.24%
Sales Q/Q
10.17%
Insider Own
1.25%
Insider Trans
0.00%
Inst Own
103.51%
Inst Trans
0.05%
ROA
32.63%
ROE
50.72%
ROIC
30.24%
Gross Margin
71.36%
Oper. Margin
36.93%
Profit Margin
116.08%
SMA20
0.47%
SMA50
0.39%
SMA200
7.72%
Trades
Shs Outstand
73.81M
Shs Float
72.88M
52W High
25.15 -9.37%
52W Low
16.52 37.95%
Volatility
2.92% 2.65%
ATR (14)
0.64
RSI (14)
50.28
Beta
0.34
Rel Volume
0.34
Avg Volume
794.31K
Volume
182,928
Perf Week
-3.23%
Perf Month
6.40%
Perf Quarter
-0.52%
Perf Half Y
15.10%
Perf YTD
14.01%
Perf Year
13.44%
Perf 3Y
79.03%
Perf 5Y
69.95%
Perf 10Y
116.43%
Prev Close
23.14
Price
22.79
Change
-1.51%
Date Action Analyst Rating Change Price Target Change
Feb-17-26Initiated BTIG Research Buy $35
Sep-30-25Initiated Goldman Sell $17
Aug-11-25Initiated Oppenheimer Outperform $45
Jul-14-25Initiated H.C. Wainwright Buy $40
Jul-11-25Initiated Cantor Fitzgerald Overweight $26
Mar-07-25Initiated Scotiabank Sector Outperform $55
Jun-18-24Initiated Cantor Fitzgerald Overweight
Jul-20-22Initiated Goldman Neutral $16
Nov-20-17Initiated Deutsche Bank Hold $13
Jun-18-26 08:00AM
Jun-16-26 08:00AM
Jun-01-26 11:00AM
May-06-26 05:43PM
04:05PM
04:27AM Loading…
Mar-01-26 04:27AM
Feb-28-26 08:26AM
06:45AM
Feb-26-26 01:48PM
Feb-25-26 08:17PM
05:08PM
04:05PM
Feb-24-26 01:14PM
01:02PM
Feb-19-26 08:21AM
08:00AM Loading…
08:00AM
Feb-18-26 09:17AM
Feb-04-26 07:55AM
Jan-08-26 08:23AM
Dec-21-25 09:57AM
Dec-12-25 04:56PM
Dec-11-25 06:35PM
Nov-25-25 07:00AM
Nov-14-25 04:47AM
Nov-05-25 06:40PM
05:33PM
04:05PM
Nov-04-25 08:00AM
Oct-31-25 09:00AM
Oct-30-25 07:55AM
05:02AM Loading…
Oct-23-25 05:02AM
Oct-21-25 08:00AM
Oct-20-25 08:00AM
Oct-14-25 07:30AM
Oct-10-25 06:21AM
Oct-07-25 09:40AM
08:00AM
Sep-17-25 02:27PM
Aug-26-25 07:00AM
Aug-13-25 08:00AM
Aug-12-25 04:05PM
Aug-11-25 09:33AM
Aug-06-25 05:06PM
04:05PM
Jun-12-25 07:00AM
Jun-10-25 06:00AM
Jun-03-25 07:00AM
May-20-25 06:00AM
May-08-25 08:54AM
May-07-25 05:52PM
04:05PM
Apr-11-25 12:30AM
Mar-21-25 06:35PM
Mar-14-25 06:17PM
Mar-12-25 05:08PM
Mar-05-25 07:00AM
Feb-26-25 04:35PM
04:04PM
Feb-06-25 07:00AM
Dec-17-24 07:25AM
Dec-16-24 07:00AM
01:15AM
Nov-26-24 07:00AM
Nov-21-24 11:14PM
Nov-12-24 04:05PM
Nov-06-24 05:23PM
04:05PM
Sep-04-24 07:00AM
Jul-31-24 10:54PM
05:51PM
04:05PM
Jul-09-24 01:30PM
Jun-27-24 08:00AM
Jun-18-24 09:51AM
Jun-03-24 07:00AM
May-31-24 07:30AM
May-20-24 04:06AM
May-10-24 02:04PM
May-08-24 10:57PM
05:09PM
04:05PM
07:00AM
Apr-24-24 07:00AM
Mar-04-24 04:01PM
Feb-29-24 04:56PM
04:37PM
04:05PM
Feb-14-24 02:44AM
Jan-10-24 06:16PM
Nov-18-23 07:03AM
Nov-03-23 06:00AM
Nov-01-23 05:32PM
04:15PM
04:05PM
Sep-19-23 08:30AM
Sep-18-23 08:00AM
Aug-25-23 04:52PM
Aug-02-23 05:18PM
04:05PM
Jul-23-23 09:22AM
Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
CEO & DirectorMr. Pavel Raifeld C.F.A.
Chief Financial OfficerMr. Stephen Basso M.B.A.
Chief Accounting Officer & SecretaryMs. Marianne Zhen CPA
Chief Commercial Officer-Innoviva Specialty TherapeuticsMs. Patricia M. Drake
MPADr. David Altarac M.D.